KHCM
HRTX icon

Kettle Hill Capital Management’s Heron Therapeutics HRTX Stock Holding History

Kettle Hill Capital Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-372,199
Closed -$5.78M – 54
2021
Q2 		$5.78M Buy
+372,199
New +$5.92M 1.02% 34

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Kettle Hill Capital Management's HRTX Position: Q3 2021 in Review

Kettle Hill Capital Management sold out of Heron Therapeutics (HRTX) in Q3 2021, closing a stake of 372,199 shares — an estimated $5.78M sold.

Kettle Hill Capital Management first reported a position in HRTX in Q2 2021 and held it in 1 quarter. The position peaked at $5.78M in Q2 2021. 197 funds tracked by Wall St. Rank hold HRTX as of Q3 2021.

  • Kettle Hill Capital Management reported no remaining Heron Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Kettle Hill Capital Management sold 372,199 Heron Therapeutics shares in Q3 2021, an estimated $5.78M.
  • Kettle Hill Capital Management first reported a position in Heron Therapeutics in Q2 2021 and held it in 1 quarter.
  • Kettle Hill Capital Management's Heron Therapeutics position peaked at $5.78M in Q2 2021.
  • 197 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2021.

Based on Kettle Hill Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.